Melissa S Putman1,2, Logan B Greenblatt1, Michael Bruce1, Taisha Joseph1, Hang Lee3, Gregory Sawicki4, Ahmet Uluer4,5, Leonard Sicilian6, Isabel Neuringer6, Catherine M Gordon2,7, Mary L Bouxsein1, Joel S Finkelstein1. 1. Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 2. Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA. 3. Massachusetts General Hospital Biostatistics Center, Boston, MA, USA. 4. Division of Pulmonology, Boston Children's Hospital, Boston, MA, USA. 5. Division of Pulmonology and Critical Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 6. Division of Pulmonology and Critical Care, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 7. Division of Adolescent and Young Adult Medicine, Boston Children's Hospital, Boston, MA, USA.
Abstract
CONTEXT: Cystic fibrosis (CF) transmembrane conductance (CFTR) dysfunction may play a role in CF-related bone disease (CFBD). Ivacaftor is a CFTR potentiator effective in improving pulmonary and nutritional outcomes in patients with the G551D-CFTR mutation. The effects of ivacaftor on bone health are unknown. OBJECTIVE: To determine the impact of ivacaftor on bone density and microarchitecture in children and adults with CF. DESIGN: Prospective observational multiple cohort study. SETTING: Outpatient clinical research center within a tertiary academic medical center. PATIENTS OR OTHER PARTICIPANTS: Three cohorts of age-, race-, and gender-matched subjects were enrolled: 26 subjects (15 adults and 11 children) with CF and the G551D-CFTR mutation who were planning to start or had started treatment with ivacaftor within 3 months (Ivacaftor cohort), 26 subjects with CF were not treated with ivacaftor (CF Control cohort), and 26 healthy volunteers. INTERVENTIONS: All treatments, including Ivacaftor, were managed by the subjects' pulmonologists. MAIN OUTCOME MEASURES: Bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT), areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry (DXA) and bone turnover markers at baseline, 1, and 2 years. RESULTS: Cortical volume, area, and porosity at the radius and tibia increased significantly in adults in the Ivacaftor cohort. No significant differences were observed in changes in aBMD, trabecular microarchitecture, or estimated bone strength in adults or in any outcome measures in children. CONCLUSIONS: Treatment with ivacaftor was associated with increases in cortical microarchitecture in adults with CF. Further studies are needed to understand the implications of these findings.
CONTEXT: Cystic fibrosis (CF) transmembrane conductance (CFTR) dysfunction may play a role in CF-related bone disease (CFBD). Ivacaftor is a CFTR potentiator effective in improving pulmonary and nutritional outcomes in patients with the G551D-CFTR mutation. The effects of ivacaftor on bone health are unknown. OBJECTIVE: To determine the impact of ivacaftor on bone density and microarchitecture in children and adults with CF. DESIGN: Prospective observational multiple cohort study. SETTING: Outpatient clinical research center within a tertiary academic medical center. PATIENTS OR OTHER PARTICIPANTS: Three cohorts of age-, race-, and gender-matched subjects were enrolled: 26 subjects (15 adults and 11 children) with CF and the G551D-CFTR mutation who were planning to start or had started treatment with ivacaftor within 3 months (Ivacaftor cohort), 26 subjects with CF were not treated with ivacaftor (CF Control cohort), and 26 healthy volunteers. INTERVENTIONS: All treatments, including Ivacaftor, were managed by the subjects' pulmonologists. MAIN OUTCOME MEASURES: Bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT), areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry (DXA) and bone turnover markers at baseline, 1, and 2 years. RESULTS: Cortical volume, area, and porosity at the radius and tibia increased significantly in adults in the Ivacaftor cohort. No significant differences were observed in changes in aBMD, trabecular microarchitecture, or estimated bone strength in adults or in any outcome measures in children. CONCLUSIONS: Treatment with ivacaftor was associated with increases in cortical microarchitecture in adults with CF. Further studies are needed to understand the implications of these findings.
Keywords:
Ivacaftor; bone microarchitecture; bone mineral density; cystic fibrosis; dual energy X-ray absorptiometry; high-resolution peripheral quantitative computed tomography
Authors: Nicolas Vilayphiou; Stephanie Boutroy; Elisabeth Sornay-Rendu; Bert Van Rietbergen; Roland Chapurlat Journal: Bone Date: 2015-10-23 Impact factor: 4.398
Authors: D Gensburger; S Boutroy; R Chapurlat; R Nove-Josserand; S Roche; M Rabilloud; I Durieu Journal: Osteoporos Int Date: 2016-05-11 Impact factor: 4.507
Authors: R M Aris; D A Ontjes; H E Buell; A D Blackwood; R K Lark; M Caminiti; S A Brown; J B Renner; W Chalermskulrat; G E Lester Journal: Osteoporos Int Date: 2002 Impact factor: 4.507
Authors: J N Tsai; A V Uihlein; S M Burnett-Bowie; R M Neer; N P Derrico; H Lee; M L Bouxsein; B Z Leder Journal: J Clin Endocrinol Metab Date: 2016-03-10 Impact factor: 5.958
Authors: Troy D Pashuck; Sarah E Franz; Molly K Altman; Clive H Wasserfall; Mark A Atkinson; Thomas J Wronski; Terence R Flotte; Michael S Stalvey Journal: Pediatr Res Date: 2009-03 Impact factor: 3.756
Authors: Andrea Kelly; Justine Shults; Sogol Mostoufi-Moab; Shana E McCormack; Virginia A Stallings; Joan I Schall; Heidi J Kalkwarf; Joan M Lappe; Vicente Gilsanz; Sharon E Oberfield; John A Shepherd; Karen K Winer; Mary B Leonard; Babette S Zemel Journal: J Bone Miner Res Date: 2018-10-29 Impact factor: 6.741
Authors: Michael S Stalvey; Katrina L Clines; Viktoria Havasi; Christopher R McKibbin; Lauren K Dunn; W Joon Chung; Gregory A Clines Journal: PLoS One Date: 2013-11-13 Impact factor: 3.240
Authors: Rosara M Bass; Babette S Zemel; Virginia A Stallings; Mary B Leonard; Jaime Tsao; Andrea Kelly Journal: J Clin Transl Endocrinol Date: 2022-03-25
Authors: Kevin J Scully; Laura T Jay; Steven Freedman; Gregory S Sawicki; Ahmet Uluer; Joel S Finkelstein; Melissa S Putman Journal: Nutrients Date: 2022-01-12 Impact factor: 5.717